PL1732902T3 - Pochodne nukleozydów i ich terapeutyczne zastosowanie - Google Patents
Pochodne nukleozydów i ich terapeutyczne zastosowanieInfo
- Publication number
- PL1732902T3 PL1732902T3 PL05733004T PL05733004T PL1732902T3 PL 1732902 T3 PL1732902 T3 PL 1732902T3 PL 05733004 T PL05733004 T PL 05733004T PL 05733004 T PL05733004 T PL 05733004T PL 1732902 T3 PL1732902 T3 PL 1732902T3
- Authority
- PL
- Poland
- Prior art keywords
- nucleoside derivatives
- therapeutic use
- compounds
- methods
- administering
- Prior art date
Links
- 150000003833 nucleoside derivatives Chemical class 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55814104P | 2004-04-01 | 2004-04-01 | |
| EP05733004A EP1732902B1 (en) | 2004-04-01 | 2005-04-01 | Nucleoside derivatives and therapeutic use thereof |
| PCT/US2005/011313 WO2005097757A2 (en) | 2004-04-01 | 2005-04-01 | Nucleoside derivatives and therapeutic use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1732902T3 true PL1732902T3 (pl) | 2010-06-30 |
Family
ID=34979006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05733004T PL1732902T3 (pl) | 2004-04-01 | 2005-04-01 | Pochodne nukleozydów i ich terapeutyczne zastosowanie |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7405214B2 (OSRAM) |
| EP (1) | EP1732902B1 (OSRAM) |
| JP (2) | JP5001832B2 (OSRAM) |
| KR (1) | KR100926596B1 (OSRAM) |
| CN (2) | CN1980898B (OSRAM) |
| AT (1) | ATE453628T1 (OSRAM) |
| AU (1) | AU2005230676B2 (OSRAM) |
| BR (1) | BRPI0509553B8 (OSRAM) |
| CA (1) | CA2562965C (OSRAM) |
| DE (1) | DE602005018620D1 (OSRAM) |
| ES (1) | ES2334803T3 (OSRAM) |
| IN (1) | IN2014DN04587A (OSRAM) |
| MX (1) | MXPA06011141A (OSRAM) |
| PL (1) | PL1732902T3 (OSRAM) |
| WO (1) | WO2005097757A2 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9315534B2 (en) * | 2007-08-10 | 2016-04-19 | Board Of Regents Of The University Of Nebraska | Radiologic agents for monitoring alzheimer's disease progression and Evaluating a Response to Therapy and processes for the preparation of such agents |
| US20120269725A1 (en) * | 2009-12-23 | 2012-10-25 | Janine Baranowska-Kortylewicz | Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer |
| BR122022026659B1 (pt) | 2013-03-15 | 2023-05-16 | Rexahn Pharmaceuticals, Inc | Processo para a preparação de 4-amino-1-((1s,4r,5s)-2-fluoro-4,5-di- hidróxi-3-(hidroximetil)-ciclopent-2-en-1-il)-pirimidin-2(1h)-ona |
| EP4008321A1 (en) * | 2015-06-09 | 2022-06-08 | Ocuphire Pharma, Inc. | Fluorocyclopentenylcytosine for treating tumour |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6187674A (ja) * | 1984-10-06 | 1986-05-06 | Yoshitomi Pharmaceut Ind Ltd | シクロペンテン環を有する新規ヌクレオシド |
| US4975434A (en) * | 1986-05-27 | 1990-12-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antiviral and anticancer cyclopentenyl cytosine |
| KR101201552B1 (ko) * | 2000-10-18 | 2012-11-15 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| TWI299664B (en) * | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
-
2005
- 2005-04-01 WO PCT/US2005/011313 patent/WO2005097757A2/en not_active Ceased
- 2005-04-01 IN IN4587DEN2014 patent/IN2014DN04587A/en unknown
- 2005-04-01 BR BRPI0509553A patent/BRPI0509553B8/pt active IP Right Grant
- 2005-04-01 ES ES05733004T patent/ES2334803T3/es not_active Expired - Lifetime
- 2005-04-01 PL PL05733004T patent/PL1732902T3/pl unknown
- 2005-04-01 MX MXPA06011141A patent/MXPA06011141A/es active IP Right Grant
- 2005-04-01 DE DE602005018620T patent/DE602005018620D1/de not_active Expired - Lifetime
- 2005-04-01 CN CN2005800178253A patent/CN1980898B/zh not_active Expired - Fee Related
- 2005-04-01 CN CN2010105546004A patent/CN102091072A/zh active Pending
- 2005-04-01 JP JP2007506347A patent/JP5001832B2/ja not_active Expired - Lifetime
- 2005-04-01 EP EP05733004A patent/EP1732902B1/en not_active Expired - Lifetime
- 2005-04-01 KR KR1020067022856A patent/KR100926596B1/ko not_active Expired - Lifetime
- 2005-04-01 AT AT05733004T patent/ATE453628T1/de not_active IP Right Cessation
- 2005-04-01 US US11/095,686 patent/US7405214B2/en not_active Expired - Lifetime
- 2005-04-01 CA CA2562965A patent/CA2562965C/en not_active Expired - Lifetime
- 2005-04-01 AU AU2005230676A patent/AU2005230676B2/en not_active Expired
-
2012
- 2012-03-12 JP JP2012054597A patent/JP2012107072A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN1980898A (zh) | 2007-06-13 |
| KR20070012685A (ko) | 2007-01-26 |
| BRPI0509553B8 (pt) | 2021-05-25 |
| KR100926596B1 (ko) | 2009-11-11 |
| IN2014DN04587A (OSRAM) | 2015-07-10 |
| CA2562965A1 (en) | 2005-10-20 |
| WO2005097757A3 (en) | 2005-12-08 |
| BRPI0509553B1 (pt) | 2019-06-18 |
| BRPI0509553A (pt) | 2007-09-18 |
| ES2334803T3 (es) | 2010-03-16 |
| EP1732902A2 (en) | 2006-12-20 |
| MXPA06011141A (es) | 2007-08-14 |
| WO2005097757A2 (en) | 2005-10-20 |
| EP1732902B1 (en) | 2009-12-30 |
| CN1980898B (zh) | 2011-01-12 |
| US7405214B2 (en) | 2008-07-29 |
| AU2005230676B2 (en) | 2010-10-07 |
| AU2005230676A1 (en) | 2005-10-20 |
| DE602005018620D1 (de) | 2010-02-11 |
| CA2562965C (en) | 2013-10-29 |
| CN102091072A (zh) | 2011-06-15 |
| US20050222185A1 (en) | 2005-10-06 |
| JP2007531736A (ja) | 2007-11-08 |
| JP2012107072A (ja) | 2012-06-07 |
| ATE453628T1 (de) | 2010-01-15 |
| JP5001832B2 (ja) | 2012-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000180A1 (en) | NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | |
| DE602006014579D1 (de) | Heteroalkylgebundene pyrimidinderivate | |
| EA200800665A1 (ru) | АГЕНТЫ ДЛЯ ПРЕДУПРЕЖДЕНИЯ И ЛЕЧЕНИЯ НАРУШЕНИЙ, ВКЛЮЧАЮЩИХ МОДУЛИРОВАНИЯ RyR РЕЦЕПТОРОВ | |
| MX2010013682A (es) | Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos. | |
| MXPA06009475A (es) | Derivados de quinazolina y usos terapeuticos de los mismos. | |
| IL176110A0 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| NO20080475L (no) | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | |
| MY143367A (en) | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | |
| IL189191A0 (en) | Thiazolyl piperidine derivatives useful as h3 receptor modulators | |
| TW200600506A (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
| TW200612936A (en) | Indole derivatives | |
| IL191763A0 (en) | Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators | |
| IL191751A0 (en) | Pyrrolo[2,3-c]pyridine derivatives | |
| TW200722081A (en) | New therapeutic combinations for the treatment or prevention of depression | |
| TW200800946A (en) | Substituted piperazines as metabotropic glutamate receptor antagonists | |
| TW200626158A (en) | Naphthaline derivatives | |
| TW200639156A (en) | New compounds | |
| MX2007006387A (es) | Derivados de piridina 3-substituidos como antagonistas h3. | |
| MX2008012093A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos. | |
| MX2007007027A (es) | Derivados piperazinilpiridina como agentes anti-obesidad. | |
| TW200637817A (en) | 5-aminoindole derivatives | |
| MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. | |
| NO20080671L (no) | Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister | |
| TW200732304A (en) | Piperidine derivatives | |
| PL1732902T3 (pl) | Pochodne nukleozydów i ich terapeutyczne zastosowanie |